154 related articles for article (PubMed ID: 10194547)
1. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
2. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
[TBL] [Abstract][Full Text] [Related]
3. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
Hasinoff BB; Yalowich JC; Ling Y; Buss JL
Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
5. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
[TBL] [Abstract][Full Text] [Related]
6. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
7. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
9. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
[TBL] [Abstract][Full Text] [Related]
10. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
11. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
13. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
[TBL] [Abstract][Full Text] [Related]
14. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
Wu X; Patel D; Hasinoff BB
J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
[TBL] [Abstract][Full Text] [Related]
15. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
Malisza KL; Hasinoff BB
Free Radic Biol Med; 1996; 20(7):905-14. PubMed ID: 8743977
[TBL] [Abstract][Full Text] [Related]
18. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
19. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Kik K; Szmigiero L
Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane (ICRF-187).
Weiss G; Loyevsky M; Gordeuk VR
Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]